Pancreatic Cancer Europe is a European multi-stakeholder platform which aims at bringing together experts from all over Europe including academics, physicians, politicians, patient groups, journalists and industry with a common interest and willingness to improve care for patients with pancreatic cancer.
Pancreatic Cancer Europe joins the Consultation on the EU Beating Cancer Plan
7 May 2020
In February, the European Commission opened a consultation on its Europe Beating Cancer Plan. Inviting all citizens to bring their expertise to the table in order to propose a Plan that, according to the Commission’s own words, “puts European citizens at the centre”.
As a multi-stakeholder Platform, PCE is rich from a variety of point of views and perspectives on life with pancreatic cancer. The Platform has developed a contribution to be shared with the European Commission in order to ensure that pancreatic cancer and its current challenges are taken into account in the next structuring effort against cancer at the European level.
From diagnosis to post-therapy life, we have worked on a contribution that encompasses all the stages of living with pancreatic cancer, in hope of improving every stage for patients, their families and their carers. We also ensured to remind the Commission of the major funding effort that is necessary for research, as well as of the need for EU Registries on pancreatic cancer, in line with the core claims of PCE since its creation.
Pancreatic Cancer Europe will follow with attention the next developments of this Plan and keep its advocacy actions up and running to always push for the consideration of pancreatic cancer in public policies across Europe.
Short-Stay Scientific Award: a word from our awardee Marina Cihova
16 October 2019
In summer 2019 I received a Short-Stay Scientific Award for Early-Career Investigators granted by Pancreatic Cancer Europe. The award enabled me to travel to Madrid and spend a month at the Medical Oncology Research Laboratory in Ramon y Cajal Health Research Institute. I joined research team of Prof. Alfredo Carrato Mena which has an extensive experience in pancreatic cancer research. The main objective of my stay was to learn and develop relevant pre-clinical study models of patient-derived pancreatic tumor organoids with the aim to improve diagnostic capacities in pancreatic cancer. The traditionally and most commonly used 2D cell lines in pancreatic cancer research lack many important characteristics of the tumor from which they were originally derived. Organoids can be perceived as cancer cells grown in 3D structures while preserving the true anatomy of solid tumors and hence e.g. heterogeneous access to nutrients or oxygen or relevant cell-cell interactions. They are derived from a tumor tissue obtained from patient undergoing surgery and today they are perceived as the most relevant and crucial preclinical model. The short scientific stay provided me an opportunity to learn deriving organoids from patient pancreatic tumor samples and propagate them for further necessary experiments. In our ongoing pancreatic cancer projects at my home institution a proper preclinical model was lacking and therefore I’m very delighted I could have established and implemented this model which will help us immensely to get further in our research. The lab environment at the hosting institution was very welcoming and the stay opened up opportunities for future cooperation which I am very thankful for.
Pancreatic Cancer Europe partners with iPAAC!
9 October 2019
Pancreatic Cancer Europe is delighted to announce a new partnership with The Innovative Partnership for Action Against Cancer (iPAAC) Joint Action. The platform brings together over 24 associated partners across Europe, and aims to develop innovative approaches to advances in cancer control and further the development of cancer prevention. IPAAC's work is divided into 10 work packages, PCE will be contributing to work package 7 Cancer Information and Registries and work package 8: Challenges in Cancer Care. We are excited to contribute to the work of iPAAC Joint Action and we are looking forward to what this fruitful partnership will bring!
Pancreatic Cancer Europe’s General Assembly Meeting – Barcelona, 4 July 2019
4 July 2019
The Annual General Meeting of Pancreatic Cancer Europe took place in Barcelona, Spain, at the occasion of the World Congress on Gastrointestinal Cancer. The general assembly meeting aimed to give an overview of the achievements in first half of 2019, and to discuss the strategic objectives and the actions identified in the long-term vision developed by the Board of PCE in April. The present members of the Platform were able to express their expectations for the Platform and explain how they will be able to further contribute to its development. Members will once again be called to participate to an Extraordinary Annual General Meeting in October. More details will be communicated soon to all PCE members. Thanks again for the successful AGM and looking forward to seeing all members next year for the 2020 AGM.
Pancreatic Cancer Advocacy Workshop award
4 July 2019
In April 2019 took place the Pancreatic Cancer Advocacy Workshop (PACAW) in Rome. Members of the Platform were invited to join the Heads of the “Awareness and Diagnosis” and “National Support” workstream, Ali Stunt and Antonella Cardone, to learn the know-how of designed advocacy strategies in their countries. To this occasion, Members were offered to create a strategy to compete for the Pancreatic Cancer Advocacy Workshop award. Two very successful proposals were submitted by our Scottish and Polish members, Pancreatic Cancer Scotland and EuropaColon Poland. EuropaColon Poland finally won the award, and the reward, a one-year support from the PCE Secretariat to the implementation of their national activities, based on mental health in cancer patients and adopting a psycho-oncological approach to cancer care. Congratulations to both groups for their submission, thank you to all the members who participated to the Workshop and see you next year for a third edition of the PACAW!
Short-Stay Scientific Award Winner Decided
4 July 2019
Thanks to a collaboration with the European Pancreatic Club, the Research Workstream of PCE was able to organise, this year for the first time, the creation of a Short-Stay Scientific Award (S3A) for Early-Career Investigators (ECI). The S3A was associated with a grant of 3000€ for the successful researcher to travel to a different country and stay for up to 3 months in a foreign research institution. The winner of this year is Marina Cihova, a Slovakian researcher at the Slovak Academy of Sciences, within the Cancer Research Institute, will go abroad and stay for a month in Madrid, Spain, at the Ramon y Cajal Health Research Institute. She will work to develop relevant pre-clinical study models of patient-derived pancreatic tumour organoids. This research project aims at improving diagnostic capacities in pancreatic cancer. The award, which is designed to foster collaboration and cooperation between research teams all over Europe, has been attributed to Marina Cihova during this year’s Annual General Meeting. Her stay will happen in September and will hopefully result in Marina’s success!
Participation to EPC Bergen and ESMO GI WCGIC
26 – 29 June 2019
Pancreatic Cancer Europe had the opportunity to hold a booth at the 51st European Pancreatic Club Meeting in Bergen, Norway, on June 26-29, and at the 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain. During the Bergen EPC meeting, Nuria Malats, Sorin Barbu and Alfredo Carrato, Board members of the PCE association, each gave an insightful presentation. The beautiful city of Bergen was the perfect host for this meeting. Next year, the 52nd EPC Meeting will happen in Paris, and PCE of course looks forward to being represented again by the Secretariat and its Board members. PCE was also represented at ESMO GI. PCE had endorsed the event officially. Amid sponsors and other umbrella organisations such as Digestive Cancers Europe (DiCE), PCE was able to push forward the cause of pancreatic cancer. Two very successful meetings, both in terms of organisation and content, which led to PCE inviting many more passionate people to join the platform and contribute, at the European or national level, to the improvement of pancreatic cancer diagnosis, care and support to patient everywhere. We sincerely thank EPC and ESMO GI for allowing PCE to be able to advocate for pancreatic cancer at their Meetings.
Endorsement of ESMO GI 2019
Pancreatic Cancer Europe is proud to endorse ESMO World Congress on Gastrointestinal Cancer 2019. The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field – encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. ESMO GI will take place in Barcelona, Spain – from 3 to 6 July 2019. More information on their website www.worldgicancer.com.
Pancreatic Cancer Europe – Research
PCE Short-Term Scientific Stay Award
The PCE Board members, in particular Dr Nuria Malats, are glad to announce you the launch of the PCE short-term scientific stay award (ECI) on 2 April 2019!
The grant will allow Early Career Investigators to go to an institution or laboratory in another European country (from the EU) not only to foster collaboration, but also to learn a new technique or to take measurements using instruments and/or methods not available in their own institution/laboratory.
The applications for this grant are now opened until 31 May 2019. Please send your application to firstname.lastname@example.org
The result of the grant will be unveiled during European Pancreas Club Congress in Bergen in June 2019.
Do not hesitate to write directly to the Secretariat for any further information regarding the grant (email@example.com).
Pancreatic Cancer 2019 Elections Manifesto
Pancreatic Cancer Europe was founded to bring the fight against pancreatic cancer to the European Union through a single voice. By enabling collaboration on research, registries and by raising awareness we have one goal: decrease the severe mortality of pancreatic cancer.
The European Union must have a central role in this duty. In order to ensure action by the European Union, a strong commitment by all the European institutions and policymakers is needed.
In May 2019, European citizens will elect our representatives in the European Parliament. These elections are a key moment for pancreatic cancer patients: the next European Parliament has the opportunity to ensure that the European Union delivers against pancreatic cancer.
To enable a strong commitment by the future policymakers, Pancreatic Cancer Europe is launching the Pancreatic Cancer 2019 Elections Manifesto. By signing the Manifesto, candidates to the European Elections from all countries and political parties will show their commitment to ensure that the European Union takes appropriate action against pancreatic cancer, by taking 8 key actions.
We invite all candidates to show their commitment and share the Pancreatic Cancer 2019 Elections Manifesto. Together we can tackle this deadly disease.
Pancreatic Cancer Heatmap now online!
Following several months of development, we are happy to unveil the PCE heatmap. Conceived as a powerful tool to compare the pancreatic cancer patients’ situation in each European country, the heatmap provides information on awareness situation, national policy, diagnosis, research… We are always looking for more data and information to enrich the heatmap. Should you want to add some data for your country, please contact directly the Secretariat.
Did you know that Pancreatic Cancer has the lowest survival rate of all cancers?
Help us to reverse the Trend!
Pancreatic cancer is currently the 4th leading cause of death by cancer in Europe. If no action is taken, it is set to be 2nd by 20203.
Launched in July 2014 a call for action on pancreatic cancer by Members of the European Parliament has been the key driver for the activities of the platform. Since its launch, Pancreatic Cancer Europe has been developping the Pancreatic Cancer Declaration, in order to ensure real change in European policies for pancreatic cancer patients.
Patients affected with pancreatic cancer lose 98% of their healthy life expectancy at the point of diagnosis5.
Today, a diagnosis of pancreatic cancer is generally associated with a death sentence and few patients are alive one year after diagnosis, while an earlier diagnosis could help reduce the mortality of the disease. If diagnosed in time, chances of survival increase.
- Farthing, M, Roberts, S, Samuel D, Williams D, et al. Survey of digestive health across Europe: Final report. Part 1: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe, United European Gastroenterology Journal, December 2014 vol. 2 no. 6 539-543
- Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E, et al. European cancer mortality predictions for the year 2013. Annals of Oncol. 2013; 24:792-800
- Pancreatic Cancer Action Network. The alarming rise of pancreatic cancer deaths in The United States: Why we need to stem the tide today, 2012. www.pancan.org/wp-content/uploads/2013/01/incidence_report_2012_executive_summary.pdf [Last accessed April 2014]
- Carrato et al, 2015. “A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.” DOI 10.1007/s12029-015-9724-1
- Carrato A, Falcone A, Ducreux, M, Valle, J, Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C, Parthenaki I. A systematic review of the burden of pancreatic cancer in Europe: Real-world impact on survival, quality-of-life, and costs. J Gastrointest Cancer 2015 Sep;46(3):201-11